AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
Acquiring Company
Daewon Pharmaceutical
Acquired Company
GC Biopharma
North ChungcheongManufacturingBiotechnologyPharmaceuticalBiotechnologyHealth CareBiopharmapharmaceuticalsDescription
Daewon Pharmaceutical has completed the acquisition of Shinbaro, an osteoarthritis treatment developed by GC Biopharma. Following a partnership that transitioned from co-marketing to ownership of related assets, Daewon is now producing the drug in-house. This move enhances their capabilities in manufacturing and ensures a stable supply chain. The company aims to strengthen its position in the musculoskeletal treatment market.
Fundz sees it the moment Daewon Pharmaceutical makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
M&A Insights
Based on deal dataFrequently asked
Who acquired GC Biopharma?
GC Biopharma was acquired by Daewon Pharmaceutical, based in North Chungcheong. The deal was reported on September 21, 2026. Daewon Pharmaceutical is a South Korean company specializing in pharmaceutical products. The company focuses on musculoskeletal treatments and has developed several innovative therapies. Daewon Pharmaceutical is privately held and operates in Manufacturing.
When did Daewon Pharmaceutical acquire GC Biopharma?
Daewon Pharmaceutical's acquisition of GC Biopharma was reported on September 21, 2026. Daewon Pharmaceutical has completed the acquisition of Shinbaro, an osteoarthritis treatment developed by GC Biopharma. Following a partnership that transitioned from co-marketing to ownership of related assets, Daewon is now producing the drug in-house. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does GC Biopharma do?
GC Biopharma is a leading biopharmaceutical company specializing in the development and production of therapeutic proteins and vaccines. With a commitment to innovation, GC Biopharma aims to improve global health through high-quality products. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.